Generic

India Launches First Biosimilar for World's Top-selling Drug

Dec 11, 2014

Reuters

India-based Cadila Healthcare has launched the first biosimilar version of the world's top-selling anti-inflammatory drug adalimumab -- for a fifth of its U.S. price.

The branded version of adalimumab is sold under the name Humira by U.S.-based AbbVie, and costs $1,000 per vial in the United States. The biosimilar, available in India, will be priced at $200 a vial.

 Read the Reuters press release